PHARMACOKINETIC ASPECTS OF L-DEPRENYL (SELEGILINE) AND ITS METABOLITES

被引:104
作者
HEINONEN, EH
ANTTILA, MI
LAMMINTAUSTA, RAS
机构
关键词
D O I
10.1038/clpt.1994.204
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
l-Deprenyl (selegiline), an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), is rapidly absorbed from the gastrointestinal tract and distributed into tissues. The reaction between MAO and selegiline takes place in two steps. The initial reversible reaction is followed by an irreversible reaction in which selegiline is bound covalently to the flavin part of the enzyme. Studies with positron emission tomography have shown retention of selegiline in brain areas with high MAO-B activity, including striatal structures, hippocampus, thalamus, and substantia nigra. Inhibition of MAO-B in vivo takes place rapidly; for example, platelet MAO is inhibited almost totally within the first 60 minutes after a single 10 mg oral dose of the drug. The recovery of MAO after inhibition depends on the organ and species in question, In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days. Selegiline is metabolized into l-(-)-desmethylselegiline, l-(-)-methamphetamine, and l-(-)amphetamine mainly in the liver through the microsomal P-450 system. The stereoselectivity of the metabolites is maintained; no racemic transformation takes place. All three main metabolites are found in human serum, cerebrospinal fluid, and urine, and l-(-)-methamphetamine accounts for most of the metabolite pool. The metabolites are excreted mainly via urine, l-(-)-Desmethylselegiline has been shown to be an irreversible inhibitor of MAO-B in the rat and in humans.
引用
收藏
页码:742 / 749
页数:8
相关论文
共 66 条
  • [1] INCREASED BINDING OF H-3 L-DEPRENYL IN SPINAL-CORDS FROM PATIENTS WITH AMYOTROPHIC-LATERAL-SCLEROSIS AS DEMONSTRATED BY AUTORADIOGRAPHY
    AQUILONIUS, SM
    JOSSAN, SS
    EKBLOM, JG
    ASKMARK, H
    GILLBERG, PG
    [J]. JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1992, 89 (1-2) : 111 - 122
  • [2] TURNOVER OF BRAIN MONOAMINE-OXIDASE MEASURED INVIVO BY POSITRON EMISSION TOMOGRAPHY USING L-[C-11]DEPRENYL
    ARNETT, CD
    FOWLER, JS
    MACGREGOR, RR
    SCHLYER, DJ
    WOLF, AP
    LANGSTROM, B
    HALLDIN, C
    [J]. JOURNAL OF NEUROCHEMISTRY, 1987, 49 (02) : 522 - 527
  • [3] BENAKIS A, 1981, PHARMACOKINETIC STUD
  • [4] MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327
    BENCH, CJ
    PRICE, GW
    LAMMERTSMA, AA
    CREMER, JC
    LUTHRA, SK
    TURTON, D
    DOLAN, RJ
    KETTLER, R
    DINGEMANSE, J
    DAPRADA, M
    BIZIERE, K
    MCCLELLAND, GR
    JAMIESON, VL
    WOOD, ND
    FRACKOWIAK, RSJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) : 169 - 173
  • [5] L-DEPRENYL PLUS L-PHENYLALANINE IN THE TREATMENT OF DEPRESSION
    BIRKMAYER, W
    RIEDERER, P
    LINAUER, W
    KNOLL, J
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1984, 59 (01) : 81 - 87
  • [6] BIRKMAYER W, 1977, LANCET, V1, P439
  • [7] BLACKWELL B, 1963, LANCET, V2, P849
  • [8] BORBE HO, 1990, J NEUR TR S, P131
  • [9] PHENYLETHYLAMINERGIC MODULATION OF CATECHOLAMINERGIC NEUROTRANSMISSION
    BOULTON, AA
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1991, 15 (02) : 139 - 156
  • [10] DELLACORTE L, 1980, BIOCHEM PHARMACOL, V29, P891